Home Cart 0 Sign in  

[ CAS No. 1419949-20-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1419949-20-4
Chemical Structure| 1419949-20-4
Structure of 1419949-20-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1419949-20-4 ]

Related Doc. of [ 1419949-20-4 ]

Alternatived Products of [ 1419949-20-4 ]

Product Details of [ 1419949-20-4 ]

CAS No. :1419949-20-4 MDL No. :MFCD28167762
Formula : C27H34N4O5 Boiling Point : -
Linear Structure Formula :- InChI Key :DYGBNAYFDZEYBA-UHFFFAOYSA-N
M.W : 494.58 Pubchem ID :136237316
Synonyms :
TNKS656
Chemical Name :N-(Cyclopropylmethyl)-2-(4-(4-methoxybenzoyl)piperidin-1-yl)-N-((4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide

Calculated chemistry of [ 1419949-20-4 ]

Physicochemical Properties

Num. heavy atoms : 36
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.56
Num. rotatable bonds : 10
Num. H-bond acceptors : 7.0
Num. H-bond donors : 1.0
Molar Refractivity : 138.3
TPSA : 104.83 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -8.51 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.83
Log Po/w (XLOGP3) : 1.13
Log Po/w (WLOGP) : 1.44
Log Po/w (MLOGP) : 0.87
Log Po/w (SILICOS-IT) : 4.05
Consensus Log Po/w : 2.06

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.2
Solubility : 0.309 mg/ml ; 0.000624 mol/l
Class : Soluble
Log S (Ali) : -2.93
Solubility : 0.588 mg/ml ; 0.00119 mol/l
Class : Soluble
Log S (SILICOS-IT) : -6.14
Solubility : 0.000355 mg/ml ; 0.000000718 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.92

Safety of [ 1419949-20-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1419949-20-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1419949-20-4 ]
  • Downstream synthetic route of [ 1419949-20-4 ]

[ 1419949-20-4 ] Synthesis Path-Upstream   1~7

  • 1
  • [ 1419957-49-5 ]
  • [ 1419954-10-1 ]
  • [ 1419949-20-4 ]
YieldReaction ConditionsOperation in experiment
24%
Stage #1: With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 20℃; for 0.5 h;
Stage #2: at 20℃;
Example 5: N-Cyclopropylmethyl-2-[4-(4-methoxy-benzoyl)-piperidin-1-yl]-N-(4-oxo- -tetrahydro-4H-pyrano[4, 3-d]pyrimidin-2-ylmethyl)-acetamideTo a solution of [4-(4-methoxy-benzoyl)-piperidin-1-yl]-acetic acid (0.071 g, 0.26 mmol, 1 eq.) and DIEA (0.089 mL, 0.51 mmol, 2 eq.) in 2 mL of DMF was added HATU (0.107 g, 0.281 mmol, 1.1 eq.). The resulting mixture was stirred at room temperature for 30 min. 2-[(Cyclopropylmethyl-amino)-methyl]-3,5,7,8-tetrahydro-pyrano[4,3-d]pyrimidin-4-one (0.06 g, 0.26 mmol, 1 eq.) in 1 mL of DMF was added and the mixture was stirred at room temperature overnight. After 18 h, the reaction mixture was diluted with H20 (10 mL) and extracted with dichloromethane (3 x 50 mL). The combined organics were concentrated and purified by preparative HPLC (20-100percent CH3CN/H20 over 10 min with 0.1 percent TFA, sun fire C18 OBD 50x50 mm column with flow rate of 60 mL/min) to give the title compound as a white solid (0.03 g, 24percent). 1H NMR (400 MHz, MeOD) δ ppm 7.94 - 8.07 (m, 2 H), 6.98 - 7.10 (m, 2 H), 4.64 - 4.70 (m, 1 H), 4.54 - 4.60 (m, 1 H), 4.44 - 4.52 (m, 2 H), 4.28 - 4.37 (m, 1 H), 3.94 - 3.99 (m, 1 H), 3.91 - 3.95 (m, 2 H), 3.88 (s, 3 H), 3.67 - 3.80 (m, 2 H), 3.40 - 3.61 (m, 1 H), 3.33 - 3.40 (m, 2 H), 3.09 - 3.27 (m, 2 H), 2.50 - 2.72 (m, 2 H), 1 .92 - 2.26 (m, 4 H), 0.83 - 1 .15 (m, 1 H), 0.12 - 0.67 (m, 4 H). HRMS calculated for C27H35N405 495.2607, found (ESI, [M + H]+) 495.2606. MS (ESI) m/z 495.3 (M+H)+. Retention time: 2.89 min (5-95percent CH3CN/H20 over 7.75 min with 0.1 percent formic acid, Inertsil ODS3 100x3 mm C18 column with flow rate of 1.0 mL/min).Alternate procedure 1To a well stirred suspension of 2-[(Cyclopropylmethyl-amino)-methyl]-3,5,7,8-tetrahydro- pyrano[4,3-d]pyrimidin-4-one (15.66 g, 57.6 mmol) in dichloromethane (600 mL) was added 2-(4-(4-methoxybenzoyl)piperidin-1-yl)acetic acid (16.45 g, 59.3 mmol), followed by triethylamine (24 mL, 173 mmol), 1 H-benzo[d][1 ,2,3]triazol-1 -ol hydrate (21 .41 g, 140 mmol) and N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1 ,3-diamine hydrochloride (13.26 g, 69.2 mmol). The resulting yellow suspension was stirred for 12 h, filtered and then washed with water three times (250 mL, 150 mL, then 50 mL). The organic layer was washed twice with brine (50 mL), dried with Na2S04, filtered and concentrated in vacuo (33.34 g). The residue was dissolved in 750 mL dichloromethane, and washed with a pH 9 KHC03/K2C03 solution (2 x1 OOmL). The organic layer was washed twice with brine (50 mL), dried with Na2S04, filtered and concentrated in vacuo (23.4 g). The crude material was dissolved in approximately 25 mL MeOH resulting in an orange solution and placed in a freezer overnight to form a slurry. The mixture was filtered, washed with MeOH and dried in vacuo to yield 21 .959 g of the title compound as a white solid. HRMS calculated for C27H34N405 495.2607, found (ESI, [M + H]+), 495.2607, retention time = 3.717 min. CHN analysis: calculated (results). C 65.57 (65.17), H 6.93 (6.64), N 1 1 .33 (1 1 .39). Alternate procedure 2To [4-(4-methoxy-benzoyl)-piperidin-1 -yl]-acetic acid (306 mg, 0.85 mmol) in DMF (3 ml.) was added with HATU (485 mg, 1.28 mmol) and DIEA (0.37 ml_, 275 mg, 2.12 mmol). This was sonicated, stirred for 30 min and then 2-[(cyclopropylmethyl-amino)- methyl]-3,5,7,8-tetrahydro-pyrano[4,3-d]pyrimidin-4-one (200 mg, 0.85 mmol) in 1 ml_ DMF was added to the mixture. Then it was stirred at room temperature for 16 hours and the mixture was concentrated to dryness. This was purified by silica gel column (eluted with 0-10percent methanol in dichloromethane) followed by trituration with methanol to give a white solid as the title compound (93 mg, 0.19 mmol, 22percent yield), m/z = 495.3 (M+H).
Reference: [1] Patent: WO2013/12723, 2013, A1, . Location in patent: Page/Page column 99-101
[2] Journal of Medicinal Chemistry, 2013, vol. 56, # 16, p. 6495 - 6511
  • 2
  • [ 1417917-59-9 ]
  • [ 1419949-20-4 ]
Reference: [1] Patent: WO2013/12723, 2013, A1,
[2] Patent: WO2013/12723, 2013, A1,
[3] Journal of Medicinal Chemistry, 2013, vol. 56, # 16, p. 6495 - 6511
  • 3
  • [ 127956-11-0 ]
  • [ 1419949-20-4 ]
Reference: [1] Patent: WO2013/12723, 2013, A1,
[2] Patent: WO2013/12723, 2013, A1,
[3] Journal of Medicinal Chemistry, 2013, vol. 56, # 16, p. 6495 - 6511
  • 4
  • [ 76362-12-4 ]
  • [ 1419949-20-4 ]
Reference: [1] Patent: WO2013/12723, 2013, A1,
[2] Journal of Medicinal Chemistry, 2013, vol. 56, # 16, p. 6495 - 6511
  • 5
  • [ 1419957-43-9 ]
  • [ 1419949-20-4 ]
Reference: [1] Patent: WO2013/12723, 2013, A1,
[2] Journal of Medicinal Chemistry, 2013, vol. 56, # 16, p. 6495 - 6511
  • 6
  • [ 29943-42-8 ]
  • [ 1419949-20-4 ]
Reference: [1] Patent: WO2013/12723, 2013, A1,
[2] Patent: WO2013/12723, 2013, A1,
  • 7
  • [ 1419954-19-0 ]
  • [ 1419949-20-4 ]
Reference: [1] Patent: WO2013/12723, 2013, A1,
Same Skeleton Products
Historical Records